List of Excipients in Branded Drug DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	CETYL ALCOHOL
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	D&C YELLOW NO. 10
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	DIBUTYL SEBACATE
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	ETHYLCELLULOSE
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	FD&C RED NO. 40
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	FD&C YELLOW NO. 6
Amneal Pharmaceuticals of New York LLC	DEXTROAMPHETAMINE SULFATEEXTENDED-RELEASE	dextroamphetamine sulfate	0115-1702	GELATIN

Dextroamphetamine Sulfate Extended-Release: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 2, 2026

Dextroamphetamine sulfate extended-release is a mature controlled-release stimulant market centered on multiparticulate capsule technology, generic competition, and supply reliability. The strongest commercial opportunities are differentiated release profiles, abuse-deterrent design, pediatric dose flexibility, improved storage stability, and dependable controlled-substance manufacturing. The original Dexedrine Spansule exclusivity has expired, so new entrants generally require an abbreviated new drug application or, for a clinically differentiated product, a 505(b)(2) pathway.

What is the commercial profile of dextroamphetamine sulfate extended-release?

Dextroamphetamine sulfate extended-release capsules contain the dextro isomer of amphetamine sulfate and are used primarily for attention-deficit/hyperactivity disorder and narcolepsy. The reference product is Dexedrine Spansule, historically marketed by SmithKline Beecham and later associated with predecessor and successor stimulant portfolios.

The product is a Schedule II controlled substance. Commercial performance depends on FDA approval, Drug Enforcement Administration quota availability, controlled-substance distribution controls, pharmacy stocking behavior, and manufacturing continuity.

Attribute	Commercial relevance
Active ingredient	Dextroamphetamine sulfate
Dosage form	Extended-release oral capsule
Reference product	Dexedrine Spansule
Common strengths	5 mg, 10 mg, and 15 mg for the reference product
FDA pathway for ordinary generic	ANDA
Controlled-substance classification	Schedule II
Primary clinical markets	ADHD and narcolepsy
Main competitive products	Dextroamphetamine immediate-release tablets, mixed amphetamine salts ER, lisdexamfetamine, methylphenidate ER
Main formulation platform	Multiparticulate extended-release beads or pellets
Primary commercial constraint	Controlled-substance quota and reliable supply

The extended-release product occupies a narrower market than mixed amphetamine salts extended-release and lisdexamfetamine. Its advantages are once-daily dosing, direct active-drug delivery, and a potentially lower cost than branded prodrugs. Its disadvantages include controlled-substance abuse liability, limited manufacturer participation, and a smaller prescriber base.

What excipients are used in dextroamphetamine sulfate extended-release capsules?

The exact excipient composition depends on the manufacturer and formulation platform. FDA labeling identifies inactive ingredients for approved products, but labels do not always disclose the full quantitative composition or manufacturing process.

A multiparticulate dextroamphetamine extended-release capsule may contain the following excipient classes:

Excipient class	Function in the formulation	Commercial and regulatory considerations
Core substrate or sugar spheres	Provides a carrier for drug loading	Controls bead size, coating uniformity, and dose distribution
Binder	Holds dextroamphetamine sulfate on the substrate	Affects drug loading, friability, and content uniformity
Film former	Creates the controlled-release membrane	Polymer choice directly affects dissolution and food sensitivity
Pore former	Creates diffusion channels in the membrane	Can accelerate release and reduce coating thickness
Plasticizer	Improves coating flexibility	Excess can cause tackiness, migration, or altered release
Anti-tacking agent	Prevents pellet agglomeration during coating	Supports continuous processing and yield
Lubricant or glidant	Supports capsule filling	Must be controlled to avoid segregation and dissolution effects
Capsule shell	Contains the multiparticulate dose	Gelatin and hypromellose options affect supply and patient acceptability
Colorant or opacifier	Supports product identification and light protection	Subject to permitted-color and labeling requirements
Buffer or pH modifier	Controls drug release or microenvironmental pH	May alter stability and gastrointestinal release
Antioxidant or stabilizer	Protects vulnerable components	More relevant where excipient or coating degradation is observed

The reference product's technology is associated with sustained-release pellets. A generic does not need to copy the exact excipients or process, but it must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements.

Which excipient properties matter most?

The highest-value excipient variables are particle size distribution, compressibility, hygroscopicity, coating permeability, and compatibility with dextroamphetamine sulfate.

Dextroamphetamine sulfate is highly water soluble. That creates a formulation challenge: an uncoated or weakly coated multiparticulate system can release the drug rapidly. The release membrane therefore has to provide adequate diffusion resistance without producing excessive dose dumping.

The most important development controls are:

1. Drug-layer uniformity across pellets.
2. Coating weight gain and coating thickness.
3. Membrane integrity after storage.
4. Dissolution across acidic and neutral media.
5. Capsule fill-weight uniformity.
6. Resistance to alcohol-induced release acceleration.
7. Stability under high humidity.
8. Performance after sprinkling or opening, if such administration is claimed.

Excipients should be selected from established pharmaceutical supply chains with documented compendial status, low nitrosamine risk, and sufficient capacity for controlled-substance manufacturing.

What formulation strategy offers the strongest commercial opportunity?

A multiparticulate bead system remains the most practical platform for a generic or differentiated extended-release product. It permits a controlled-release profile while preserving dose flexibility and capsule-based manufacturing.

Multiparticulate bead technology

Multiparticulates can combine immediate-release and extended-release populations. A formulation might use:

• Uncoated or lightly coated beads for early exposure.
• Moderately coated beads for intermediate release.
• Heavily coated beads for late release.

This approach allows the developer to shape the plasma profile without changing the active ingredient. The commercial advantage is dose proportionality across strengths and the possibility of maintaining a similar manufacturing platform for multiple products.

pH-independent release

A pH-independent membrane is commercially attractive because gastrointestinal pH varies across patients and can affect exposure. Ethylcellulose-based systems, often combined with pore-forming excipients, can provide diffusion-controlled release over a broad pH range.

A pH-responsive system may offer a narrower or more distinctive release profile, but it introduces greater risk of food effects, interpatient variability, and regulatory scrutiny.

Alcohol-resistant release

Stimulant products require careful evaluation of alcohol-induced dose dumping. A release membrane that maintains controlled delivery in the presence of alcohol may support product differentiation and lifecycle management. The claim should be based on validated in vitro and, where necessary, in vivo evidence rather than on excipient selection alone.

Sprinkle and administration flexibility

A capsule that can be opened and sprinkled on soft food may improve pediatric use. The formulation must demonstrate that the pellets remain intact, the dose is recoverable, and the release profile is preserved. This opportunity is technically attractive but can create additional labeling, stability, and bioequivalence requirements.

What FDA regulatory pathway applies to a new product?

A conventional generic of an approved dextroamphetamine sulfate extended-release capsule would normally proceed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The ANDA must address:

• Pharmaceutical equivalence.
• Bioequivalence.
• Comparative dissolution.
• Inactive ingredient safety.
• Manufacturing controls.
• Stability.
• Container-closure performance.
• Controlled-substance handling.
• Labeling consistency with the reference product, subject to permitted differences.

A 505(b)(2) application may be relevant if the product has a meaningful formulation or delivery difference that cannot be supported through a standard ANDA. Examples could include a new sprinkle presentation, a materially different release mechanism, or a distinct abuse-deterrent platform. The 505(b)(2) route can require additional clinical or pharmacokinetic evidence and may carry greater development cost.

Dextroamphetamine sulfate extended-release products are not biologics. Biosimilar risk is therefore not applicable. Competitive risk comes from small-molecule generics, authorized generics, branded amphetamine products, and therapeutic substitutes.

What patents protect dextroamphetamine sulfate extended-release products?

The original composition and extended-release rights associated with Dexedrine Spansule are understood to be expired. The commercially relevant patent questions now concern later patents covering specific release systems, bead structures, capsule configurations, manufacturing processes, or methods of use.

A patent search should separate four categories:

Patent category	Potential scope	Generic-entry significance
Active-ingredient patent	Dextroamphetamine sulfate itself	Generally expired for this mature molecule
Extended-release formulation patent	Coating, pellet architecture, or release profile	May block a particular formulation
Manufacturing patent	Drug layering, coating, curing, or pellet processing	Can create process risk without blocking all products
Method-of-use patent	ADHD, narcolepsy, dosing schedule, or patient subgroup	Relevant mainly to labeling and Paragraph IV strategy

Orange Book listing status must be checked by reference product, strength, dosage form, and marketing applicant. FDA's Approved Drug Products with Therapeutic Equivalence Evaluations identifies listed patents and regulatory exclusivities for approved products. A formulation patent is commercially relevant only if it is listed, enforceable, and applicable to the proposed generic's product or labeling strategy. [1]

Because patent listings and expiration dates can change through corrections, delistings, terminal disclaimers, and litigation outcomes, an investment-grade freedom-to-operate analysis should use the current FDA Orange Book and USPTO records rather than historical Dexedrine patent summaries.

When does dextroamphetamine sulfate extended-release lose exclusivity?

The original product has already lost its principal exclusivity protections. The market is therefore primarily genericized, subject to any later-listed formulation or method-of-use patent.

Exclusivity issue	Current strategic interpretation
Original molecule exclusivity	Expired
Original extended-release product exclusivity	Expired or no longer the principal market barrier
New chemical entity exclusivity	Not available for a mature dextroamphetamine product
Pediatric exclusivity	Historical product-specific issue, not a current general barrier
Orphan exclusivity	Not expected for the ordinary ADHD indication
Generic approval barrier	Bioequivalence, manufacturing, controlled-substance compliance, and any live patents
Market-entry barrier	Supply capacity and quota may be more important than patent protection

What Paragraph IV challenges and litigation affect the market?

A Paragraph IV certification would be relevant only if the proposed ANDA applicant believes a listed patent is invalid, unenforceable, or not infringed. For a mature dextroamphetamine sulfate extended-release product, the main risk is not the original molecule patent. It is a later formulation or method patent that may be listed against a current reference product.

Potential litigation issues include:

• Whether a pellet coating limitation is present in the generic.
• Whether a proposed release profile infringes a formulation claim.
• Whether a process patent can be asserted against an independently manufactured generic.
• Whether the applicant can use a section viii statement to omit a patented method of use.
• Whether a patent was properly listed in the Orange Book.
• Whether the reference product has an active commercial sponsor capable of enforcing the patent.

No broad biosimilar litigation pathway applies. Settlement agreements, if any, would need to be reviewed through FDA patent certifications, court dockets, and Federal Trade Commission pharmaceutical settlement disclosures. A historical settlement involving another amphetamine product should not be treated as evidence of a settlement for dextroamphetamine sulfate extended-release.

How strong is the patent estate for dextroamphetamine sulfate extended-release?

The patent estate is likely weak at the molecule level and potentially moderate for narrowly defined formulation platforms.

Strength assessment

Layer	Relative strength	Reason
Active ingredient	Low	Mature compound with long-expired foundational rights
Broad extended-release concept	Low	Controlled-release stimulant technology is well developed
Specific pellet architecture	Moderate	Claims may distinguish coating layers, polymer ratios, or release windows
Manufacturing process	Moderate	Process claims can be difficult to design around if tied to critical quality attributes
Abuse-deterrent formulation	Variable	Strength depends on demonstrated resistance and claim breadth
Method of use	Low to moderate	Scope may be limited by existing stimulant treatment practice
Trade secrets	Moderate	Coating parameters, curing conditions, and scale-up controls may remain valuable

Trade secrets may create a more durable commercial barrier than patents. A company with validated pellet coating, high yield, low dose variability, and reliable controlled-substance handling can compete even when patent protection is limited.

What commercial opportunities exist for new excipient platforms?

Pediatric dose flexibility

Pediatric ADHD treatment creates demand for precise dose titration. Opportunities include multiple strengths, sprinkle administration, reduced capsule size, and improved swallowing characteristics. A multiparticulate system can support these features without changing the active ingredient.

Alcohol-resistant delivery

A controlled-release formulation that limits alcohol-triggered rapid release could support a differentiated label or branded-generic positioning. The product would need comparative abuse-related and pharmacokinetic evidence sufficient for FDA review.

Improved storage stability

A low-moisture capsule and robust film coating may reduce potency drift, pellet agglomeration, and dissolution changes during storage. Stability improvements can reduce product losses and support distribution through pharmacies with variable environmental conditions.

Reduced excipient burden

A high-drug-load formulation can reduce capsule size and simplify the inactive ingredient profile. This may improve patient acceptance, but a high drug load can increase coating defects, segregation, and dose-uniformity risk.

Non-gelatin capsule systems

Hypromellose capsules can address dietary, religious, and supply-chain preferences. They may also provide a differentiated product presentation. The formulation must account for capsule moisture transmission, brittleness, shell dissolution, and compatibility with the pellet coating.

Contract development and manufacturing

A manufacturer with expertise in multiparticulate coating and Schedule II controls could license its platform to pharmaceutical companies that lack controlled-substance infrastructure. The highest-value capabilities are:

• DEA-registered handling.
• Segregated controlled-substance areas.
• Validated pellet coating at commercial scale.
• Secure inventory reconciliation.
• Established stimulant distribution channels.
• FDA inspection history.
• Backup API and excipient suppliers.

How does dextroamphetamine sulfate extended-release compare with competing stimulants?

Product class	Key advantage	Key disadvantage	Commercial implication
Dextroamphetamine ER	Direct active-drug delivery and generic pricing	Controlled-substance risk and smaller market	Cost-focused and supply-focused opportunity
Mixed amphetamine salts ER	Broad prescriber familiarity and established brand history	More complex active mixture	Stronger branded and generic competition
Lisdexamfetamine	Prodrug design and lower abuse potential by route of administration	Higher cost and dependence on prodrug economics	Premium alternative and major substitute
Methylphenidate ER	Large clinical market and multiple delivery platforms	Different tolerability and response profile	Major therapeutic substitute
Dextroamphetamine IR	Flexible titration and rapid onset	More frequent dosing and greater diversion concern	Competes for patients needing dose control

The product is unlikely to win solely through low price. Reliable availability, predictable duration, simplified administration, and a differentiated abuse-related profile provide stronger commercial positioning.

What generic launch risks exist?

The main launch risks are operational rather than foundational patent risks.

1. Controlled-substance quota limitations can delay scale-up.
2. API sourcing may be concentrated among a small number of qualified suppliers.
3. Pellet coating variability can create dissolution failures.
4. A small market can make validation and launch inventory expensive relative to sales.
5. Pharmacy purchasing may shift quickly during shortages and reverse after supply normalizes.
6. Formulation differences can produce food-effect or dose-dumping concerns.
7. A new excipient may trigger additional FDA review and weaken the ANDA strategy.
8. DEA, state, and supply-chain requirements increase compliance costs.
9. A branded competitor may use authorized-generic or contracting strategies to defend volume.
10. Schedule II diversion controls restrict promotional and distribution flexibility.

What licensing and partnership structures are commercially attractive?

The most practical transaction structures are:

• Platform licensing for multiparticulate extended-release technology.
• Co-development with a company holding an ANDA-ready controlled-substance facility.
• API and formulation supply agreements with dual-source provisions.
• Authorized-generic arrangements with a reference-product or branded-generic sponsor.
• Regional licensing where one party holds FDA rights and another holds commercial distribution.
• Milestone-based deals tied to FDA filing, approval, commercial launch, and supply continuity.

A licensing target should be evaluated on patent coverage, freedom to operate, FDA inspection history, controlled-substance registrations, batch-scale evidence, dissolution similarity, and manufacturing yield. A formulation patent without commercial-scale process capability has limited transaction value.

What is the revenue exposure and competitive outlook?

Revenue exposure is concentrated in a relatively small generic stimulant segment rather than in a large protected-brand franchise. The product can generate attractive returns when supply is constrained, but shortage-driven pricing is unstable and may invite additional entrants.

The best commercial case is a platform product with:

• Three or more dose strengths.
• A validated multiparticulate process.
• Low dependence on a single API source.
• A pediatric-friendly administration option.
• Demonstrated alcohol and food-effect performance.
• A credible DEA quota plan.
• A differentiated capsule or excipient profile.
• Manufacturing economics suitable for a modest-volume market.

The weakest case is a conventional copy with no supply advantage, no formulation differentiation, and dependence on one controlled-substance manufacturing site.

Key Takeaways

• Dextroamphetamine sulfate extended-release is a mature, genericized controlled-substance market.
• The principal reference technology is a multiparticulate sustained-release capsule.
• Excipient strategy should focus on coating permeability, dose uniformity, humidity stability, alcohol resistance, and pH-independent release.
• The strongest product opportunities are pediatric sprinkle administration, reliable supply, improved stability, and differentiated release performance.
• Foundational molecule and original product exclusivity are no longer the main barriers.
• Later formulation and method-of-use patents must be checked in the current FDA Orange Book and USPTO records.
• Generic-entry risk is driven more by DEA quota, API supply, process capability, and manufacturing reliability than by broad composition patents.
• Biosimilar risk does not apply because dextroamphetamine sulfate is a small molecule.
• A 505(j) ANDA is the ordinary pathway; a 505(b)(2) application may be appropriate for a materially differentiated delivery system.
• The most defensible commercial asset is a validated controlled-substance manufacturing platform combined with formulation know-how and reliable supply.

FAQs

Can a generic dextroamphetamine extended-release product use different excipients from Dexedrine Spansule?

Yes. A generic may use different inactive ingredients if the formulation meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling.

Is dextroamphetamine sulfate extended-release eligible for an authorized generic strategy?

Potentially. An authorized generic requires a sponsor with the appropriate product rights, manufacturing capability, and controlled-substance distribution infrastructure. The commercial value depends on the reference product's current market position and supply strategy.

Can a dextroamphetamine extended-release capsule be reformulated as a tablet?

Yes, but a tablet would generally require a different product strategy and may not qualify as an ordinary generic of the capsule. The regulatory pathway could involve a 505(b)(2) application and additional clinical or pharmacokinetic work.

What excipient issue presents the greatest technical risk?

The greatest risk is uncontrolled release caused by inadequate coating integrity or excessive membrane permeability. Because dextroamphetamine sulfate is highly water soluble, small changes in coating weight, pore formation, or curing can materially affect dissolution.

Is an abuse-deterrent dextroamphetamine formulation commercially viable?

It can be viable if the product demonstrates meaningful resistance to manipulation or route-of-administration abuse and receives a commercially useful label. The development cost and evidentiary burden are higher than for a conventional generic.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. FDA.

4. U.S. Food and Drug Administration. (2017). General principles for evaluating abuse-deterrent formulations for opioid drug products. FDA.

5. U.S. Food and Drug Administration. (2024). Dexedrine Spansule prescribing information. FDA-approved labeling.

6. U.S. Food and Drug Administration. (2019). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. FDA.

7. U.S. Food and Drug Administration. (2024). Drug shortages and controlled-substance availability information. FDA.